Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U04 Substudy 04B
NCT05845814Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2023
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of favezelimab, vibostolimab in urothelial carcinoma (UC), sponsored by Merck & Co.. Started Jun 2023; status: active, not recruiting.
02
Drugs
favezelimabvibostolimab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05845814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05845814.